# US 2024/0189409 A1 · Personalized Site-Specific Immunomodulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189409 A1
- Document ID: US20240189409A1
- Status: Published application
- Kind: A1
- Application number: 18/224,769
- Filed: 2023-07-21
- Published: 2024-06-13
- Earliest claimed: 2010-07-26
- Assignees: Qu Biologics Inc.
- Applicants: Qu Biologics Inc.
- Inventors: Harold David Gunn; Salim Dhanji; Brett Anthony Premack; Michael Tak Huai Chow
- Web page: https://patentgrep.com/patent/US20240189409A1

## CPC

- A61K 39/0258: {Escherichia}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/0266: {Klebsiella}
- A61K 39/0275: {Salmonella}
- A61K 39/05: {Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella}, Corynebacterium; Propionibacterium {(Mycobacterium A61K39/04)}
- A61K 39/085: Staphylococcus
- A61K 39/092: {Streptococcus}
- A61K 39/095: Neisseria
- A61K 39/102: {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/46: Viral antigens
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/70: {Multivalent vaccine}
- A61K 2239/49: Breast
- A61K 2239/54: Pancreas
- A61K 2239/58: Prostate
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of provoking an immune response in an inflammatory bowel disease (IBD) patient by intradermal or subcutaneous injection of a formulation consisting essentially of whole killed E. coli cells, wherein the formulation is administered by repeated subcutaneous or intradermal injection at least every other day for at least two weeks.

### Claim 22 (depends on 21)

The method of claim 21, wherein the composition is administered to produce a localized skin immune response at a site of administration.
